BTK inhibitor – Page 2

Jaypirca Demonstrates Superior Efficacy Over Imbruvica in BTK Inhibitor Clash for CLL/SLL

6 months ago talkbio0Tagged BRUIN, BTK inhibitor, Chronic Lymphocytic Leukemia, CLL-314, eli lilly, head-to-head trial, Imbruvica, Jaypirca, Progression-Free Survival

Jaypirca; Imbruvica; BTK inhibitor; chronic lymphocytic leukemia; small lymphocytic lymphoma; BRUIN CLL-314; overall response rate; progression-free survival; head-to-head trial; Eli Lilly

AstraZeneca’s Calquence Combo Approved for First-Line CLL in EU

8 months ago talkbio0Tagged Amplify trial, Approved, AstraZeneca, BTK inhibitor, Calquence, Chronic Lymphocytic Leukemia, EU, First line treatment, obinutuzumab, venetoclax

AstraZeneca; Calquence; EU approval; chronic lymphocytic leukaemia; first-line treatment; venetoclax; obinutuzumab; BTK inhibitor; Amplify trial

Sanofi’s Rilzabrutinib Shows Promising Results in Phase III Trial for Immune Thrombocytopenia (ITP)

1 year ago talkbio0Tagged Autoimmune thrombocytopenia, BTK inhibitor, Clinical Research, Phase 3 Clinical Trials, Rilzabrutinib, sanofi

Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study